Vaccine Development (DiavaX)

Scientists Discover Action Mechanism of Diabetes Vaccine

Published in Vaccine Weekly, June 29th, 1998

Anergen, Inc., Redwood City, California, announced in a recent study that its functional genomics vaccine stimulates antibodies that target the interaction of autoreactive white blood cells in autoimmunity and protects diabetes-prone non-obese diabetic (NOD) mice from the onset and progression of diabetes.

The data was presented at the Annual Meeting of the American Diabetes Association (ADA) in Chicago, Illinois. Anergen anticipates that Phase I clinical (safety) trials of the compound, DiavaX, will be initiated within a year.

In the study, Anergen scientists treated NOD mice before development of diabetes symptoms (5 weeks) or after the onset of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1998-06-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry